Skip to main content

Advertisement

Table 1 Natural polymorphism proportions in gag domains and drug binding positions across 8 HIV-1 subtypes and CRFs (%)

From: Functional conservation of HIV-1 Gag: implications for rational drug design

  B A1 C D F1 G 01_AE 02_AG Mean
Matrix[132/13] 57.6/38.5 62.1/46.2 59.1/46.2 64.4/53.8 52.3/46.2 66.7/61.5 61.4/46.2 56.1/30.8 59.9/46.2
Capsid[231/98] 27.3/30.6 34.2/33.7 29.4/29.6 27.7/27.6 31.2/37.8 30.3/28.6 28.1/28.6 27.3/27.6 29.4/30.5
p2[14/8] 71.4/62.5 64.3/62.5 64.3/62.5 64.3/62.5 57.1/62.5 71.4/62.5 64.3/62.5 50.0/50.0 63.4/60.9
NC[55/17] 56.4/58.8 41.8/35.3 38.2/41.2 36.4/29.4 34.5/23.5 54.5/58.8 43.6/35.3 34.5/41.2 42.5/40.4
p1[16/0] 37.5/- 25.0/- 31.2/- 43.8/- 25.0/- 31.2/- 31.2/- 12.5/- 29.7/-
p6[52/0] 76.9/- 69.2/- 69.2/- 55.8/- 65.4/- 61.5/- 69.2/- 57.7/- 65.6/-
Mean 45.2/36.8 46.6/36.8 43.4/34.6 42.8/32.4 41.2/38.2 47.0/37.5 44.0/33.1 39.0/30.9 43.6/35.0
  1. Each gag protein is demonstrated with its total AA and drug binding positions (e.g. Matrix [132/13]: 132 AA positions/13 drug binding positions). Natural polymorphism proportion (%) is indicated for each protein and subtype with respect to the total number of AAs and to the number of drug binding positions (e.g. 57.6/38.5 shows that for subtype B matrix, 57.6% of all 132 positions and 38.5% of 13 drug binding positions are polymorphic). Mean values across gag domains and across HIV-1 subtypes are indicated in the last row and column respectively.